Saudi Arabia Pharmaceutical CDMO Market, By Product (API, Synthetic, Solid, Liquid, Biotech, Drug Product, Oral Solid Dose, Semi-solid Dose, Liquid Dose, Others), By Work Flow (Clinical, Commercial), By Application (Oncology, Small Molecule, Biologics, Infectious Diseases, Neurological Disorders, Cardiovascular Diseases, Metabolic Disorders, Autoimmune Diseases, Respiratory Diseases, Ophthalmology, Gastrointestinal Disorders, Hormonal Disorders, Hematological Disorders, Others), By Region, Competition, Forecast & Opportunities, 2021-2031F

Key Insights	Details
Forecast Period	2027-2031
Market Size (2025)	USD 456.78 Million
CAGR (2026-2031)	9.81%
Fastest Growing Segment	Biologics
Largest Market	Northern & Central
Market Size (2031)	USD 800.86 Million

Market Overview

The Saudi Arabia Pharmaceutical CDMO Market will grow from USD 456.78 Million in 2025 to USD 800.86 Million by 2031 at a 9.81% CAGR. The Saudi Arabia Pharmaceutical Contract Development and Manufacturing Organization market encompasses outsourced services related to drug development, clinical trials, and commercial manufacturing for pharmaceutical and biotechnology companies. Key market drivers include the comprehensive Vision 2030 initiative aimed at localizing pharmaceutical production, substantial government investments in healthcare infrastructure, increasing prevalence of chronic diseases necessitating pharmaceutical interventions, and strategic partnerships fostering technology transfer. According to the Saudi Food and Drug Authority, in 2025, the drug sector recorded 9 licensed drug manufacturing factories, highlighting foundational industrial growth.

However, a significant challenge impeding market expansion is the complexity and time-consuming nature of regulatory approval processes by the Saudi Food and Drug Authority for new formulations and advanced therapies, which can delay market entry for innovative products.

Key Market Drivers

Vision 2030 Drives Local Manufacturing and Biopharma Capacity
Saudi Arabia's Vision 2030 and its Healthcare Sector Transformation Initiatives are fundamentally reshaping the pharmaceutical Contract Development and Manufacturing Organization market by prioritizing local manufacturing and self-sufficiency. This strategic direction aims to reduce import dependency and foster a robust domestic pharmaceutical industry, encouraging both local and international companies to invest in the Kingdom's production capabilities. The focus on localizing production extends to advanced therapies, driving the establishment of modern facilities. For instance, in 2025, MS Pharma inaugurated a USD 50 million biologics manufacturing plant in Saudi Arabia, a development serving both local and international markets and aligning directly with Vision 2030's objectives to enhance biopharmaceutical capabilities.

Public Investment Accelerates CDMO Infrastructure and Clusters
Concurrently, robust government investment and funding support are critical accelerators for the Saudi Arabia Pharmaceutical CDMO Market. These substantial financial commitments are channeled towards developing state-of-the-art infrastructure, enhancing research and development, and attracting foreign direct investment. According to the International Trade Administration, in 2024, the Saudi government dedicated SAR 214 billion, approximately US$57.1 billion, to the healthcare sector. This significant funding underpins the expansion of pharmaceutical industrial clusters and fosters a favorable environment for CDMO operations. According to pharmaphorum, in January 2026, the broader Saudi pharmaceutical and medical device market included 206 licensed companies reporting total investments exceeding SR10 billion.

Download Free Sample Report

Key Market Challenges

SFDA Regulatory Complexity and Delays
A significant challenge impeding the expansion of the Saudi Arabia Pharmaceutical Contract Development and Manufacturing Organization market is the intricate and lengthy regulatory approval processes imposed by the Saudi Food and Drug Authority for innovative formulations and advanced therapies. This complexity directly hampers market growth by extending the time required for new products to reach commercialization, thereby increasing development costs and investment risks for both pharmaceutical companies and their CDMO partners. The extended timelines can deter international pharmaceutical and biotechnology firms from selecting Saudi CDMOs, as swift market entry is often a critical factor in competitive drug development.

Ongoing Resource Strain Despite Streamlining Efforts
The inherently time-consuming nature of these regulatory pathways for novel products means CDMOs must allocate greater resources and manage longer project cycles, which can strain operational capacities and delay revenue generation. According to the Saudi Food and Drug Authority, in 2025, a "Reliance Pathway for Clinical Trials" initiative significantly reduced study approval times by 74% compared to the standard track for advanced therapies and biotechnology products. While this demonstrates an effort to streamline, the prior lengthy duration highlights the fundamental regulatory hurdles that still demand extensive resources and expertise from CDMOs to navigate, impacting their ability to rapidly innovate and scale.

Key Market Trends

Rising focus on biologics and advanced therapies manufacturing
The market is increasingly characterized by a strong focus among CDMOs on developing capabilities for biologics and advanced therapies manufacturing. This shift is critical as these complex modalities represent a growing segment of global pharmaceutical expenditure, requiring highly specialized production infrastructure and expertise. CDMOs are positioning themselves to handle sophisticated processes such as cell and gene therapies and monoclonal antibodies. For instance, according to Tanmeya Capital, in June 2025, King Faisal Specialist Hospital and Research Centre and Germfree Laboratories announced the establishment of the first Advanced Therapy Medicinal Product (ATMP) manufacturing campus in Riyadh, directly supporting the localization of high-value biopharmaceutical production. This trend enables the Saudi Arabia Pharmaceutical CDMO market to move beyond traditional small-molecule manufacturing into higher-value, technology-intensive services.

Expansion of domestic API production and upstream CDMO opportunities
Another significant trend influencing the Saudi Arabia Pharmaceutical CDMO market is the enhancement of domestic Active Pharmaceutical Ingredient (API) production. Historically, the Kingdom has been largely dependent on imported APIs, creating a strategic imperative for localization to bolster supply chain resilience and self-sufficiency. CDMOs are crucial in this endeavor, providing the manufacturing capacity and technical know-how to develop and produce APIs locally. According to pharmaphorum, in January 2026, in the article 'Saudi pharma's rise as a global CDMO destination: Investment, infrastructure, and competitive edge', the active pharmaceutical ingredient (API) CDMO market alone earned over USD $2.8 billion in 2024, indicating substantial activity and investment in this core supply sector. This emphasis on domestic API production creates new opportunities for CDMOs to engage in upstream manufacturing, thereby strengthening the entire pharmaceutical value chain within Saudi Arabia.

Segmental Insights

Biologics Growth Fueled by Vision 2030, the NIDLP, and SFDA Regulatory Acceleration
The Biologics segment stands out as the fastest-growing area within the Saudi Arabia Pharmaceutical CDMO Market, driven primarily by the strategic imperatives of Saudi Vision 2030 and the National Industrial Development and Logistics Programme (NIDLP). These national initiatives prioritize diversifying the economy and transforming the Kingdom into a regional pharmaceutical manufacturing hub, significantly reducing reliance on imported medicines. The increasing prevalence of chronic diseases further fuels demand for advanced biologic therapies, necessitating specialized production capabilities. Entities like the Public Investment Fund-backed Lifera, a biopharmaceutical CDMO, are crucial in developing domestic biologics manufacturing capacity. Furthermore, the Saudi Food and Drug Authority (SFDA) actively streamlines regulatory processes to support faster approval and market access for biologic drugs, fostering a conducive environment for this specialized segment's rapid expansion.

Regional Insights

Strategic Location, Infrastructure, and Regulatory Oversight Drive the Northern & Central Saudi CDMO Market
The Northern & Central region leads the Saudi Arabia Pharmaceutical CDMO Market due to its strategic geographic positioning, offering close proximity to key domestic markets and access to international trade routes. Riyadh, as the capital, serves as a central business hub, boasting a well-developed infrastructure and modern industrial zones that house advanced pharmaceutical manufacturing facilities. The region further benefits from a concentration of major population centers, robust healthcare infrastructure, and a high density of hospitals and specialty clinics. This environment, combined with the stringent regulatory oversight of the Saudi Food and Drug Authority, ensures quality and safety standards, fostering a favorable setting for pharmaceutical contract development and manufacturing operations.

Recent Developments

• In October 2025, WuXi AppTec, a global pharmaceutical Contract Research, Development, and Manufacturing Organization (CRDMO), signed two strategic memoranda of understanding (MoUs) with NEOM and the Ministry of Health of Saudi Arabia. These agreements aimed to explore the localization of pharmaceutical research, development, and manufacturing capabilities within the Kingdom. The initiative laid the groundwork for establishing world-class CRDMO facilities in Saudi Arabia, specifically at Oxagon, NEOM's advanced manufacturing city, or other suitable locations. This collaboration underscored a commitment to fostering innovation and expanding the biotechnology sector within the Saudi Arabia pharmaceutical CDMO market.
• In October 2025, Lifera, a company supported by Saudi Arabia's Public Investment Fund, formalized seven strategic partnerships aimed at localizing vaccine and biopharmaceutical production. Among these agreements was a significant memorandum of understanding under a Contract Development and Manufacturing Organization (CDMO) model with Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma). This particular collaboration focused on developing local manufacturing capabilities and localizing value chains within the Saudi Arabian pharmaceutical sector. These partnerships were welcomed as crucial steps toward strengthening the national pharmaceutical ecosystem and achieving Vision 2030 objectives by enhancing domestic manufacturing capacity.
• In December 2024, Bio-Thera Solutions, a China-based biopharmaceutical company, established a partnership with Tabuk Pharmaceutical Manufacturing, a leading pharmaceutical entity in the Middle East and North Africa region. The collaboration granted Tabuk exclusive rights to manufacture, distribute, and market BAT2206, a biosimilar to ustekinumab, within Saudi Arabia. Tabuk Pharmaceutical Manufacturing was responsible for the marketing authorization, local manufacturing oversight, registration, importation, and promotion of the product in the country. This strategic agreement represented a notable development in the Saudi Arabia pharmaceutical CDMO market by localizing the production and commercialization of advanced biosimilar therapies.
• In 2024, a substantial pharmaceutical manufacturing deal valued at SAR 4 billion was concluded between Nupco, Novo Nordisk, and Sanofi in Saudi Arabia. This collaboration highlighted significant investment in the country's pharmaceutical sector, focusing on enhancing local manufacturing capabilities. The deal was part of broader investments exceeding SAR 50 billion in the health sector during 2024, contributing to the nation's efforts to increase pharmaceutical localization. Such manufacturing agreements are vital for strengthening the Saudi Arabia pharmaceutical CDMO market by facilitating the local production of medicines and fostering strategic partnerships.

Key Market Players

• Julphar
• Neopharma
• Gulf Pharmaceutical Industries
• Hikma Pharmaceuticals
• Pfizer
• Novartis
• Sanofi
• GSK
• Merck
• AstraZeneca

By Product	By Work Flow	By Application	By Region
API Synthetic Solid Liquid Biotech Drug Product Oral Solid Dose Semi-solid Dose Liquid Dose Others	Clinical Commercial	Oncology Small Molecule Biologics Infectious Diseases Neurological Disorders Cardiovascular Diseases Metabolic Disorders Autoimmune Diseases Respiratory Diseases Ophthalmology Gastrointestinal Disorders Hormonal Disorders Hematological Disorders Others	Eastern Northern & Central Western Southern

Report Scope:

In this report, the Saudi Arabia Pharmaceutical CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Saudi Arabia Pharmaceutical CDMO Market, By Product:

• API
• Synthetic
• Solid
• Liquid
• Biotech
• Drug Product
• Oral Solid Dose
• Semi-solid Dose
• Liquid Dose
• Others

• Saudi Arabia Pharmaceutical CDMO Market, By Work Flow:

• Clinical
• Commercial

• Saudi Arabia Pharmaceutical CDMO Market, By Application:

• Oncology
• Small Molecule
• Biologics
• Infectious Diseases
• Neurological Disorders
• Cardiovascular Diseases
• Metabolic Disorders
• Autoimmune Diseases
• Respiratory Diseases
• Ophthalmology
• Gastrointestinal Disorders
• Hormonal Disorders
• Hematological Disorders
• Others

• Saudi Arabia Pharmaceutical CDMO Market, By Region:

• Eastern
• Northern & Central
• Western
• Southern